The global primary immunodeficiency diseases treatment market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of primary immunodeficiency diseases and growing awareness among people about these disorders. The major factors restraining the growth of this market are high cost and lack of awareness among people about these disorders. Immunoglobulin therapy segment accounted for the largest share in 2018, due to its effectiveness in treating various types of primary immunodeficiency diseases such as common variable immune deficiency (CVID), X-linked agammaglobulinemia (XLA), Wiskott-Aldrich syndrome (WAS) and severe combined immunodeficiency (SCID). Antibiotics segment is expected to grow at a CAGR of 6% during the forecast period, owing to their effectiveness in treating bacterial infections caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae type b and Neisseria meningitidis. Hospitals accounted for the largest share in 2018 due to their availability across all regions globally. North America region accounted for the largest share in 2018 due to its advanced healthcare infrastructure coupled with high prevalence rates for primary immunodeficiency diseases such as SCID and WAS which require lifelong treatment with expensive drugs like Immunoglobulin therapy or antibiotics which are not available easily across other regions globally.
Some Of The Growth Factors Of This Market:
- Increasing prevalence of chronic diseases such as diabetes and cancer are driving the growth of the Primary Immunodeficiency Diseases Treatment market globally.
- Increasing awareness about immunodeficiency diseases is also driving the growth of this market globally.
- The increasing number of research and development activities in this field is also driving the growth of this market globally.
- Increasing government funding for research and development activities in this field is also driving the growth of this market globally.
Industry Growth Insights published a new data on “Primary Immunodeficiency Diseases Treatment Market”. The research report is titled “Primary Immunodeficiency Diseases Treatment Market research by Types (Immunoglobulin therapy, Antibiotics, Others), By Applications (Hospitals, Clinics, Others), By Players/Companies CSL Behring, Grifols, Pfizer, Takeda, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Bristol-Myers Squibb, Eli Lilly”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Primary Immunodeficiency Diseases Treatment Market Research Report
By Type
Immunoglobulin therapy, Antibiotics, Others
By Application
Hospitals, Clinics, Others
By Companies
CSL Behring, Grifols, Pfizer, Takeda, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Bristol-Myers Squibb, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Primary Immunodeficiency Diseases Treatment Market Report Segments:
The global Primary Immunodeficiency Diseases Treatment market is segmented on the basis of:
Types
Immunoglobulin therapy, Antibiotics, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- Grifols
- Pfizer
- Takeda
- Abbott
- ADMA Biologics
- Astellas
- AstraZeneca
- Baxter
- Bayer
- Bristol-Myers Squibb
- Eli Lilly
Highlights of The Primary Immunodeficiency Diseases Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunoglobulin therapy
- Antibiotics
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Primary Immunodeficiency Diseases Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Primary immunodeficiency diseases (PID) are a group of rare, life-threatening conditions that affect the immune system. PID treatments include medications and surgery to help the body fight infections.
Some of the key players operating in the primary immunodeficiency diseases treatment market are CSL Behring, Grifols, Pfizer, Takeda, Abbott, ADMA Biologics, Astellas, AstraZeneca, Baxter, Bayer, Bristol-Myers Squibb, Eli Lilly.
The primary immunodeficiency diseases treatment market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Primary Immunodeficiency Diseases Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Primary Immunodeficiency Diseases Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Primary Immunodeficiency Diseases Treatment Market - Supply Chain
4.5. Global Primary Immunodeficiency Diseases Treatment Market Forecast
4.5.1. Primary Immunodeficiency Diseases Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Primary Immunodeficiency Diseases Treatment Market Size (000 Units) and Y-o-Y Growth
4.5.3. Primary Immunodeficiency Diseases Treatment Market Absolute $ Opportunity
5. Global Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Type
5.3.1. Immunoglobulin therapy
5.3.2. Antibiotics
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Primary Immunodeficiency Diseases Treatment Demand Share Forecast, 2019-2026
9. North America Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Type
9.7.1. Immunoglobulin therapy
9.7.2. Antibiotics
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Primary Immunodeficiency Diseases Treatment Demand Share Forecast, 2019-2026
10. Latin America Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Type
10.7.1. Immunoglobulin therapy
10.7.2. Antibiotics
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Primary Immunodeficiency Diseases Treatment Demand Share Forecast, 2019-2026
11. Europe Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Primary Immunodeficiency Diseases Treatment Market Size andVolume Forecast by Type
11.7.1. Immunoglobulin therapy
11.7.2. Antibiotics
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Primary Immunodeficiency Diseases Treatment Demand Share, 2019-2026
12. Asia Pacific Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Type
12.7.1. Immunoglobulin therapy
12.7.2. Antibiotics
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Primary Immunodeficiency Diseases Treatment Demand Share, 2019-2026
13. Middle East & Africa Primary Immunodeficiency Diseases Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Primary Immunodeficiency Diseases Treatment Market Size and Volume Forecast by Type
13.7.1. Immunoglobulin therapy
13.7.2. Antibiotics
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Primary Immunodeficiency Diseases Treatment Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Primary Immunodeficiency Diseases Treatment Market: Market Share Analysis
14.2. Primary Immunodeficiency Diseases Treatment Distributors and Customers
14.3. Primary Immunodeficiency Diseases Treatment Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. CSL Behring
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Grifols
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Takeda
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Abbott
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. ADMA Biologics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Astellas
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AstraZeneca
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Baxter
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bayer
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bristol-Myers Squibb
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Eli Lilly
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook